amiodarone has been researched along with Thromboembolism in 21 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin." | 9.19 | Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Al-Khatib, SM; Amerena, J; Avezum, A; Dorian, P; Flaker, G; Garcia, D; Granger, CB; Hanna, M; Harjola, VP; Hohnloser, SH; Hylek, E; Keltai, M; Lopes, RD; Sullivan, RM; Thomas, L; Wallentin, L; Wojdyla, DM, 2014) |
| "Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin." | 9.01 | Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. ( Avendano, R; Di Biase, L; Diaz, JC; Garcia, MJ; Golive, A; Krumerman, AK; Lupercio, F; Natale, A; Quispe, R; Romero, J, 2019) |
| "Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients." | 9.01 | Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. ( Joung, B; Kim, HJ; Kim, IS; Kim, JY; Kim, TH; Lee, MH; Pak, HN; Uhm, JS; Yu, HT, 2019) |
| " The search was conducted by intersecting "quinidine," "warfarin," or "amiodarone" with "atrial fibrillation." | 8.79 | Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis. ( Gornbein, JA; Middlekauff, HR; Stevenson, WG, 1995) |
| "Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin." | 5.19 | Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Al-Khatib, SM; Amerena, J; Avezum, A; Dorian, P; Flaker, G; Garcia, D; Granger, CB; Hanna, M; Harjola, VP; Hohnloser, SH; Hylek, E; Keltai, M; Lopes, RD; Sullivan, RM; Thomas, L; Wallentin, L; Wojdyla, DM, 2014) |
| "Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin." | 5.01 | Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. ( Avendano, R; Di Biase, L; Diaz, JC; Garcia, MJ; Golive, A; Krumerman, AK; Lupercio, F; Natale, A; Quispe, R; Romero, J, 2019) |
| "Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients." | 5.01 | Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. ( Joung, B; Kim, HJ; Kim, IS; Kim, JY; Kim, TH; Lee, MH; Pak, HN; Uhm, JS; Yu, HT, 2019) |
| " The search was conducted by intersecting "quinidine," "warfarin," or "amiodarone" with "atrial fibrillation." | 4.79 | Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis. ( Gornbein, JA; Middlekauff, HR; Stevenson, WG, 1995) |
| "Clinical trials have reported a low time in therapeutic range (TTR) in patients with atrial fibrillation treated with both warfarin andamiodarone." | 3.83 | The effect of the amiodarone-warfarin interaction on anticoagulation quality in a single, high-quality anticoagulation center. ( Ege, EJ; Flaker, G; Koerber, SM; Petroski, GF; Riggs, KW; White, RD, 2016) |
| "In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 2521 patients with moderate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs), or placebo." | 2.73 | Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). ( Anderson, J; Bardy, GH; Freudenberger, RS; Halperin, JL; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Poole, J, 2007) |
| "Stroke and systemic thromboembolism are serious problems for patients with atrial fibrillation (AF), but their incidence can be substantially reduced by appropriate anticoagulation." | 2.71 | Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. ( Corley, SD; DiMarco, JP; Flaker, G; Greene, HL; Mitrani, G; Nemeth, M; Rosenfeld, LE; Safford, RE; Waldo, AL, 2005) |
| "Syncope may be a manifestation of pulmonary embolism." | 1.35 | Entrapment of a floating thrombus in the right atrium by persistent Chiari's network: a barrier to massive pulmonary embolism. ( Colizzi, C; Lombardo, A; Pennestrì, F; Rizzello, V, 2009) |
| "Amiodarone therapy was associated with maintenance of sinus rhythm, fewer alterations in drug therapy, fewer embolic episodes and fewer attempted direct current cardioversions (during a shorter follow-up period)." | 1.28 | Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. ( Frenneaux, MP; Karatasakis, G; McKenna, WJ; Poloniecki, JD; Robinson, K; Stockins, B, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Arunachalam, K | 1 |
| Maan, A | 1 |
| Chu, A | 1 |
| Avendano, R | 1 |
| Romero, J | 1 |
| Lupercio, F | 1 |
| Diaz, JC | 1 |
| Quispe, R | 1 |
| Golive, A | 1 |
| Natale, A | 1 |
| Garcia, MJ | 1 |
| Krumerman, AK | 1 |
| Di Biase, L | 1 |
| Kim, IS | 1 |
| Kim, HJ | 1 |
| Yu, HT | 1 |
| Kim, TH | 1 |
| Uhm, JS | 1 |
| Kim, JY | 1 |
| Joung, B | 1 |
| Lee, MH | 1 |
| Pak, HN | 1 |
| Flaker, G | 3 |
| Lopes, RD | 1 |
| Hylek, E | 1 |
| Wojdyla, DM | 1 |
| Thomas, L | 1 |
| Al-Khatib, SM | 1 |
| Sullivan, RM | 1 |
| Hohnloser, SH | 1 |
| Garcia, D | 1 |
| Hanna, M | 1 |
| Amerena, J | 1 |
| Harjola, VP | 1 |
| Dorian, P | 1 |
| Avezum, A | 1 |
| Keltai, M | 1 |
| Wallentin, L | 1 |
| Granger, CB | 1 |
| White, RD | 1 |
| Riggs, KW | 1 |
| Ege, EJ | 1 |
| Petroski, GF | 1 |
| Koerber, SM | 1 |
| Su, M | 1 |
| Seki, D | 1 |
| Moheet, AM | 1 |
| Sulimov, VA | 1 |
| Rutzen-Lopez, H | 1 |
| Khanna, V | 1 |
| Vkhanna, V | 1 |
| Reynolds, MR | 1 |
| Reynolds, M | 1 |
| Willich, T | 1 |
| Hammwöhner, M | 1 |
| Goette, A | 1 |
| Overbeck, P | 1 |
| Steinbigler, P | 1 |
| Haberl, R | 1 |
| Lad, V | 1 |
| DiMarco, JP | 1 |
| Waldo, AL | 1 |
| Corley, SD | 1 |
| Greene, HL | 1 |
| Safford, RE | 1 |
| Rosenfeld, LE | 1 |
| Mitrani, G | 1 |
| Nemeth, M | 1 |
| Freudenberger, RS | 1 |
| Hellkamp, AS | 1 |
| Halperin, JL | 1 |
| Poole, J | 1 |
| Anderson, J | 1 |
| Johnson, G | 1 |
| Mark, DB | 1 |
| Lee, KL | 1 |
| Bardy, GH | 1 |
| Iwamoto, J | 1 |
| Inoue, H | 1 |
| Rizzello, V | 1 |
| Lombardo, A | 1 |
| Colizzi, C | 1 |
| Pennestrì, F | 1 |
| Middlekauff, HR | 1 |
| Stevenson, WG | 1 |
| Gornbein, JA | 1 |
| Clémenty, J | 1 |
| Gencel, L | 1 |
| Poquet, F | 1 |
| Haissaguerre, M | 1 |
| Gosse, P | 1 |
| Lemétayer, P | 1 |
| Oltrona, L | 1 |
| Broccolino, M | 1 |
| Merlini, PA | 1 |
| Spinola, A | 1 |
| Pezzano, A | 1 |
| Mannucci, PM | 1 |
| Lewalter, T | 1 |
| Lüderitz, B | 1 |
| Robinson, K | 1 |
| Frenneaux, MP | 1 |
| Stockins, B | 1 |
| Karatasakis, G | 1 |
| Poloniecki, JD | 1 |
| McKenna, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000556] | Phase 3 | 0 participants | Interventional | 1995-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for amiodarone and Thromboembolism
| Article | Year |
|---|---|
Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy | 2020 |
Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; | 2019 |
Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anticoagulants; ATP Binding Cassette Transporter, Sub | 2019 |
[Novel targets in the treatment of patients with atrial fibrillation: from elimination of symptoms to improvement of clinical outcomes].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Clinical | 2010 |
Atrial fibrillation: epidemiology, prognosis and therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimida | 2011 |
[Therapy of atrial fibrillation in the critically ill].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Comorbidity; Contraindicati | 2012 |
[Pharmacological therapy for atrial fibrillation after cardiac surgery].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anticoagulants; Atrial Fibrillation; Calcium Channel Blocke | 2007 |
Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Confounding Factors, Ep | 1995 |
[Atrial fibrillation, restoration of sinus rhythm].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Contraindications; Defibrillators, Implanta | 1994 |
3 trials available for amiodarone and Thromboembolism
| Article | Year |
|---|---|
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Brazil; Cause of Deat | 2014 |
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Mod | 2005 |
Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Defibrillator | 2007 |
9 other studies available for amiodarone and Thromboembolism
| Article | Year |
|---|---|
The effect of the amiodarone-warfarin interaction on anticoagulation quality in a single, high-quality anticoagulation center.
Topics: Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Atrial Fibrillation; Drug Combinations; Female; | 2016 |
Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2017 |
[Update 2012: new European guidelines for atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Dronedarone; Germany; Humans; Long-Term Care; Pract | 2012 |
[Anticoagulation--control of heart rate--cardioversion. Therpeutic algorithm in ventricular tachycardia].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Combined Modality Therapy; | 2003 |
Recurrence of atrial fibrillation and flutter after atrial compartment operation: modified atrial incisions and role of amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cryosurgery; Heart Atria; H | 2005 |
Entrapment of a floating thrombus in the right atrium by persistent Chiari's network: a barrier to massive pulmonary embolism.
Topics: Adult; Amiodarone; Echocardiography, Transesophageal; Enzyme Inhibitors; Heart Atria; Heart Valves; | 2009 |
Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Antithrombin III; Atrial Fibrillation; Biomarkers | 1997 |
[Paroxysmal atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electric Countershock; F | 2000 |
Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study.
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Child; Cinea | 1990 |